| 204 |
Clinical Implication of Aneurysm Sac Regression After EVAR |
Taeoh Kim |
Apr. 17. 25 |
| 203 |
Optimal Imaging Surveillance After EVAR |
Sanghoon Shin |
Apr. 17. 25 |
| 202 |
How Does LIFE BTK Impact BASIL2 or BEST CLI? |
Lawrence A. Garcia |
Apr. 17. 25 |
| 201 |
When Should We Consider the Percutaneous and/or Hybrid Deep Venous Arterialization for CLTI Patients? |
Gian Battista Danzi |
Apr. 17. 25 |
| 200 |
Balloon Pulmonary Angioplasty for CTEPH in Singapore |
Soo-Teik Lim |
Apr. 17. 25 |
| 199 |
EVAR Update 2025 |
Lawrence A. Garcia |
Apr. 17. 25 |
| 198 |
Efficacy and Safety of Paclitaxel DCBs: All the Same or Different? |
Jung-Kyu Han |
Apr. 16. 25 |
| 197 |
ECMO-Related Acute Limb Ischemia: Prevention and Management |
Chul-Min Ahn |
Apr. 16. 25 |
| 196 |
The Fundamental Differences Between Large Artery Involvement and Small Vessel Disease in Critical Limb-Threatening Ischemia |
Gian Battista Danzi |
Apr. 16. 25 |
| 195 |
What Is New for BTK Therapies? |
Lawrence A. Garcia |
Apr. 16. 25 |
